Patent Issued for Engineered influenza antigenic polypeptides and immunogenic compositions thereof (USPTO 12037364).

A patent has been issued to Sanofi for engineered influenza antigenic polypeptides and immunogenic compositions. The invention aims to develop a universal vaccine for influenza by creating "mosaic" polypeptides that maximize exposure to epitopes present across multiple influenza virus strains. The method involves obtaining amino acid sequences from multiple circulating strains of influenza, aligning them, identifying known epitopes and antigenic regions, and inserting selected sequences into a structural backbone to generate a mosaic influenza polypeptide. The engineered polypeptides aim to provide improved protective immunity and broaden the coverage of current strain-specific vaccines. [Extracted from the article]